Souhaitez-vous accéder aux communiqués récents ?

ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen

ACTG Launches 2nd HIV Cure Clinical Trial in Africa Study Evaluating 2 Long-Acting Broadly Neutralizing Antibodies Given at HIV Treatment Initiation

Data demonstrate superiority of HepB-CpG vaccination over conventional hepatitis B vaccines among people living with HIV.

ACTG announced two oral presentations on tuberculosis (TB) therapy that took place at The Union Conference on Lung Health 2024, in Bali, Indonesia.

ACTG Presents Data Analysis at AIDS 2024 Showing Association between Elevated Risk of Cardiovascular Events and Abacavir Use Among People Living with HIV

PAUSE study in Africa is evaluating two long-acting broadly neutralizing antibodies

Announcing the publication of results from SLIM LIVER (also known as A5371) in the Annals of Internal Medicine.

ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies for HIV Cure

ACTG at CROI: HepB-CPG Vaccine Outperforms Standard Hepatitis B Vaccine for HIV Patients with Previous Vaccination Failures

ACTG Study Shows Long-Acting Injectable Treatment Effective for Those Struggling with Viral Suppression on Daily Oral Medication